BBB. M. Blokhin

B. M. Blokhin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


B. M. Blokhin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacoepidemiological study of treatment of frequently ill children: analysis of preferences of primary care pediatricians in choosing therapy

    by B. M. Blokhin, V. Yu. Steshin, G. I. Gordienko, E. E. Bessonov, O. V. Erenko, V. M. Buyankin, A. S. Suyundukova, Z. R. Kagirova, A. V. Korolev, N. A. Guseva

    Objective: A survey of 464 primary care pediatricians was conducted to determine the choice of therapy for a group of frequently ill children depending on their length of service: from 3 to 10 years or more.Results: Recurrent acute respiratory infections are a complex problem for treating physicians. There is no consensus on the tactics of managing a group of frequently ill children among practicing pediatricians with different lengths of service. Preventive strategies come to the forefront to minimize the frequency of acute respiratory infections.


  • The observational program “ExpertiZA”: treatment of influenza and other acute respiratory viral infections in children and the possibilities of immunorehabilitation in real clinical practice

    by Yu.V. Lobzin, A.V. Gorelov, N.A. Geppe, T.A. Chebotareva, Moscow Russian Medical Academy Of Continuing Professional Education, B.M. Blokhin, E.V. Melekhina

    Due to the high prevalence of acute respiratory viral infections (ARVI) / influenza, the problem of their treatment in children remains relevant. Due to the characteristics of the child's immune system and the damaging effects of the virus, there is a highprobability of recurrent ARVI within 3 months after the episode – the period necessary for the immune system to recover. Objective. To obtain additional data on the efficacy and safety of Ergoferon® in the treatment of ARVI in children in routine outpatient practice. Patients and methods. During the 2024/2025 epidemic season an observational study was conducted in Russia with the participation of 565 outpatient pediatricians from 347 research centers – a multicenter non-interventional observation program “ExpertiZA” involving 9,888 children aged 6 months and older diagnosed with ARVI/influenza. Primary endpoints: duration of illness, number of ARVI episodes 1 and 3 months after the end of therapy with Ergoferon® to analyze its “delayed efficacy” – the contribution of the drug's immunotropic action to the body's recovery after ARVI. The duration of potentially most severe ARVI (caused by laboratory-verified influenza viruses, virus-virus co-infections, and novel coronavirus infection) and the duration of intoxication syndrome, including fever, were assessed separately. The safety analysis included data on adverse events and monitoring of vital functions. Results. The average duration of the disease was 4.4 ± 1.7 days, fever/intoxication – 2.6 ± 1.1 days, with no significant differences depending on the patient's age. A slightly shorter duration of infection was noted for influenza A virus (4.1 ± 1.4 days) and virus-virus co-infection (3.5 ± 1.2 days). One month after the end of therapy, 84.6% of patients did not develop ARVI/influenza, and after 3 months, 70.7% did not develop ARVI/influenza. The favorable profile of the drug was confirmed: adverse events, with no significant association with the drug, were noted in only 0.08% of patients. Conclusion. The results demonstrate the drug's ability to activate protective mechanisms in the acute phase of the disease and its “delayed efficacy” in children during early and late convalescence, regardless of etiology, including virus-virus co-infections. The data obtained allow us to recommend Ergoferon® for widespread use in the treatment of ARVI, including influenza, in children, including for the prevention of recurrent episodes. Key words: acute respiratory viral infection, influenza, treatment, recovery, rehabilitation, immune system, Ergoferon

  • Antibody-based biological antiviral drugs for the prevention and treatment of acute respiratory viral infections in immunocompromised patients: focus on safety

    by Natalya Geppe, Andrey Zaplatnikov, Elena Kondyurina, Boris Blokhin, Vera Revyakina, Sagira Abdrakhmanova, Oksana Romanova, Natalia Kolosova

    The safety of drug therapy is of particular importance for immunocompromised patients. This aspect acquires high importance in the context of choosing tactics for the prevention and treatment of acute respiratory viral infections. The review presents data on the features of the antiviral immune response and common cold/influenza in patients with a burdened allergic history and a brief overview of the results of clinical studies on the effectiveness and safety of innovative biological antiviral drugs based on antibodies to biological targets – Ergoferon, Anaferon for children and Anaferon. The drugs have a targeted effect on the immune system in accordance with their pharmacological targets, have a significant evidence base, including a meta-analysis of clinical trials for each drug according to the indication "acute respiratory viral infections/influenza", as well as individual studies, including double-blind placebo-controlled randomized, with this pathology in immunocompromised patients. The article also includes the results of a generalized safety analysis of the use of the above drugs for the prevention and treatment of acute respiratory viral infections/influenza in patients with concomitant allergic and autoimmune pathology. The results of the conducted studies, meta-analyses and generalized statistical analysis of data on the use of the drugs Anaferon for children, Anaferon, Ergoferon for the prevention and treatment of acute respiratory viral infections/ influenza indicate proven efficacy and a favorable safety profile and allow us to recommend drugs for wide use with preventive and therapeutic purposes in accordance with indications, including patients with allergic and autoimmune pathology.

  • TREATMENT OPTIONS FOR COUGH IN PEDIATRIC PRACTITIONER’S ROUTINE

    by B.M. Blokhin, G.I. Gordienko, A.S. Suyundukova, I.P. Lobushkova, V.YU. Steshin

    Acute respiratory infections (ARI) are the main reason for morbidity in childhood. In ca. 90% of cases, they are accompanied by cough. The purpose of this research was to study the effectiveness and safety of the STODAL® drug in the treatment of cough in children. Materials and methods used: a multicenter prospective observational non-randomized clinical study was conducted involving 1000 outpatients with ARI aged 2 to 7 y/o and whose cough duration did not exceed 3 days from the onset of the disease. All of them were prescribed and treated with the complex homeopathic anticough drug on the day of their visit to pediatric practitioner in the outpatient hospital facilities. The patients were divided into two age groups as follows: G1 (n=500) of children aged 2 to 4 y/o and G2 (n=500) of children aged 4 years and 1 day old to 7 y/o. Results: on the 7th day of the therapy, a statistically significant decrease in the severity of daytime cough was noted: in G1 the severity of cough decreased by 1.51 points (from 2.16 to 0.65 points, p<0.001) and by 1.56 points (from 2.24 to 0.68 points, p<0.001) in G2. There was no difference in the reduction in daytime cough severity between the groups (p=0.158). The severity of night cough in G1 decreased by 1.16 points (from 1.64 to 0.48 points, p<0.001) and by 1.25 points (from 1.71 to 0.46 points, p<0.001) in G2. There were no differences in the dynamics of the severity of night cough between the groups as well (p=0.135). The proportion of patients whose cough resolved completely or became clinically insignificant on the 7th day of treatment was 98%, these patients were therefore considered recovered. Cough treatment was rated positively by 95.1% of parents/caretakers. Adverse events (AEs) were reported in 5 patients (0.5% of all cases) and there were no serious AEs among them. Conclusion: the effectiveness and safety of the STODAL® drug in the treatment of cough in ARI in children aged 2 to 7 y/o allows recommending a homeopathic drug with complex anti-inflammatory, antitussive and antimicrobial action for its inclusion in the treatment regimens starting from the first days of the disease.

  • Treatment of acute respiratory viral infection in children aged 12 to 18 years: results of a randomized clinical trial of Raphamin

    by Yu.V. Lobzin, B.M. Blokhin, N.A. Geppe, E.G. Kondyurina, O.V. Shamsheva, I.M. Melnikova, L.A. Balykova, A.V. Dmitriev, E.P. Sitnikova, H.M. Vakhitov, et al.

    Objective. To evaluate the efficacy and safety of Raphamin® in the treatment of acute respiratory viral infections (ARVI) in children. Patients and methods. A multicenter, double-blind, placebo-controlled, randomized study was conducted in an outpatient setting. Of the 435 children 12-18 years old with acute respiratory infections examined, 420 patients who met the eligibility criteria were included (n = 420), randomized 1:1 into group 1 (Raphamin®, n = 206) and group 2 (placebo, n = 214). Treatment was 5 days and follow-up was up to 14 days. Time to resolution of symptoms of acute respiratory infection (confirmed by polymerase chain reaction (PCR)) was assessed, as well as disease severity, proportion of recovered patients, worsening/complications, antipyretic medication use, and safety of therapy. Results. Patients in both groups did not differ in age and sex (mean age 14.3 ± 1.7 years and 14.2 ± 1.7 years in groups 1 and 2, respectively, p = 0.869). Time to resolution of acute respiratory infection (PCR-confirmed) symptoms in group 1 was 3.3 ± 1.7 days vs. 4.4 ± 2.6 days in group 2, p < 0.001. The proportion of patients with resolution of ARVI symptoms on days 2 and 3 of treatment in group 1 reached 13.1 and 29.5% versus 3.7%, p = 0.017, and 15.0%, p = 0.011, of patients in group 2, respectively. The studied drug was well tolerated, no cases of adverse events related to the drug administration were registered. Conclusion. The use of Raphamin® for 5 days in children 12–18 years old with acute respiratory viral infections reduced the time to resolution of all symptoms of the disease by 24 hours, led to an increase in the proportion of recovered patients on the 2–3rd day of therapy and was accompanied by a good safety profile. Key words: children, treatment, acute respiratory viral infection, antiviral therapy, Raphamin®

  • TREATMENT OPTIONS FOR COUGH IN CHILDREN WITH ACUTE RESPIRATORY INFECTION

    by B.M. Blokhin, I.P. Lobushkova, A.S. Suyundukova, A.D. Prokhorova

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

  • Open Access

    Scientific critical review of clinical trials: is the objectivity important?

    by B. M. Blokhin, V. V. Nikiforov

    In 2016, a multicenter double-blind placebo-controlled randomized clinical trial in parallel groups was completed in the Russian Federation to evaluate the efficacy of the liquid dosage form of Anaferon for children in the treatment of acute respiratory viral infections in children. The design and main results of the study are presented in the largest foreign database ClinicalTrials. gov of the National Library of Medicine of the USA. In November 2018, the collection of reports of the XIII Russian Scientific and Practical Conference with international participation “Health is the basis of human potential: problems and solutions” published the article of the Russian chemist N.N. Khromov-Borisov, where the author questions the reliability of the study of the liquid form of Anaferon for children. The presented article analyzes the legitimacy of the author’s claims. From the point of view of statistics, the analysis of N.N. Khromov-Borisov cannot be considered objective and correct, since it contains gross methodological errors.

  • Open Access

    Pharmacoepidemiology of the probiotics use in infants

    by B.M. Blokhin, A.D. Prokhorova, I.P. Lobushkova, A.S. Suyundukova, G.I. Gordiyenko, V.Yu. Steshin, Z.R. Kagirova, T.Kh. Mirzoev, M.A. Melnikova, N.V. Antipova

    Aim: to obtain clinical data on the use of probiotic drugs in infants with functional gastrointesti-nal disorders (FGIDs). Patients and Methods: a retrospective cohort study was conducted on the basis of 7 medical in-stitutions in Moscow. Database of 502 case histories of children with diagnosed disorders of in-testinal microbiocenosis was formed. The children were divided into three groups depending on the probiotic agents and other medications for GI: group 1 — medications containing up to two probiotic strains in a composition; group 2 — medications containing more than two probiotic strains in a composition; group 3 — other medications for symptomatic treatment of FGIDs. Results: 259 case histories of infants were included in the study to analyze the data of the group with FGIDs. The ratio of boys and girls was 50%. In infants on artificial nutrition, the duration of the main symptoms (abdominal pain, flatulence, diarrhea, and changes in stool consistency) was significantly longer (p=0.0002). There was the lowest indicator of the symptoms’ maximum duration in the group of symptomatic treatment for GI without probiotic products. At the same time, the symptoms’ duration in this group differed from multicomponent probiotic medications (p=0.0031), but did not differ from the group of single- and two-component drugs (p=0.15). Adding that, there was a tendency to have differences between single- and two-component drugs and multicomponent ones (p=0.08). Conclusion: multicomponent probiotic medications do not always have the predominance over the single-component. It is necessary to provide a more rational approach to the targeted probi-otic therapy prescription with a possible preference for single-component drugs to avoid a num-ber of effects associated with the multicomponent probiotics use, such as antigenic load on the gastrointestinal mucosa, competitive interaction of strains. KEYWORDS: probiotics, functional gastrointestinal disorders, baby colic, retrospective study. FOR CITATION: Blokhin B.M., Prokhorova A.D., Lobushkova I.P. et al. Pharmacoepidemiology of the probiotics use in infants . Russian Journal of Woman and Child Health. 2020;3(4):309–317. DOI: 10.32364/2618-8430-2020-3-4-309-318.


  • ROLE OF SLEEP DISORDERS IN THE DEVELOPMENT OF OBESITY AND GASTROENTEROLOGICAL PATHOLOGY IN CHILDREN

    by B.M. Blokhin, A.D. Prokhorova, A.S. Suyundukova

    Облако Mail.ru - это ваше персональное надежное хранилище в интернете.


  • Open Access

    Results of a multicentre double-blind placebo-controlled randomized trial of the liquid form of Anaferon for children in the treatment of acute upper respiratory tract infections

    by B. M. Blokhin, O. V. Shamsheva, N. L. Chernaya, I. G. Sitnikov, S. G. Lazareva, N. B. Balzerovich, O. A. Perminova, O. V. Zhiglinskaya, M. Yu. Koshavtseva, М. Ю. Кощавцева

    Acute respiratory infections (ARI) are major causes of morbidity in children. Symptomatic treatment is insufficiently effective and requires additional drugs with etiotropic action. This multi-center double blind placebo-controlled randomized clinical study with superiority model design considers a liquid formulation of Anaferon for children.Methods. The study included 142 children from 1 month to 3 years 11 month 29 days old with ARI of the upper respiratory tract. They were randomized into Anaferon for children and Placebo groups (71 in each group) via interactive voice randomization system. The treatment period was 5 days, observation period – 14 days. The average duration of the symptoms and the severity of the respiratory disease were used as primary efficacy endpoints.Results. All 142 patients were randomized and included into ITT (Intention to treat) analysis. 140 patients (70 patients in each group) were included into PP-analysis. The patients in the Anaferon for children group had better results with average duration of ARI as compared to the Placebo group (87.7±31.5h vs. 103.3±19.4h; p =0.007). The authors marked efficacy of Anaferon for children in such parameters as disease severity (ITT-analysis: p=0.0004), total severity of disease symptoms (ITT-analysis: ANOVA: “Group” factor p=0.0004; “Day” factor pConclusion. Anaferon for children proved their efficiency and safety in young children with ARI.